The Role of Estrogen and Estrogen Receptors on Cardiomyocytes: An Overview

Canadian Journal of Cardiology

Volumn 32, Issue 8, 2016, Pages 1017-1025

  Luo, Tao ^a   Kim, Jin Kyung ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS SIGNAL REGULATING KINASE 1; AROMATASE; CYCLIC AMP; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN RELATED RECEPTOR ALPHA; GLUCOSE TRANSPORTER 4; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SEX HORMONE; TRANSCRIPTION FACTOR; ESTROGEN RECEPTOR;

APOPTOSIS; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; CELL REGENERATION; CYTOTOXICITY; ENDOTHELIUM; ESTROGEN ACTIVITY; EXCITATION CONTRACTION COUPLING; GENE EXPRESSION; GENETIC SUSCEPTIBILITY; HEART CONTRACTION; HEART ELECTROPHYSIOLOGY; HEART INFARCTION; HEART MITOCHONDRION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART VENTRICLE HYPERTROPHY; HUMAN; NONHUMAN; REVIEW; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; CARDIOVASCULAR DISEASE; ENERGY METABOLISM; FEMALE; GENETIC POLYMORPHISM; GENETICS; HYPERTROPHY, LEFT VENTRICULAR; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REGENERATION;

APOPTOSIS; CARDIOVASCULAR DISEASES; ENERGY METABOLISM; ESTROGENS; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; POLYMORPHISM, GENETIC; RECEPTORS, ESTROGEN; REGENERATION;

EID: 84990003666     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2015.10.021     Document Type: Review

References (105)

1. 1 Harman, S.M., Menopausal hormone treatment cardiovascular disease: another look at an unresolved conundrum. Fertil Steril 101 (2014), 887–897.
2. 2 Rossouw, J.E., Anderson, G.L., Prentice, R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 288 (2002), 321–333.
3. 3 Grady, D., Herrington, D., Bittner, V., et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288 (2002), 49–57.
4. 4 Gurney, E.P., Nachtigall, M.J., Nachtigall, L.E., Naftolin, F., The women's health initiative trial and related studies: 10 years later: a clinician's view. J Steriod Biochem Mol Biol 142 (2014), 4–11.
5. 5 Harman, S.M., Black, D.M., Naftolin, F., et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med 161 (2014), 249–260.
6. 6 Hodis, H.N., Mack, W.J., Shoupe, D., et al. Methods and baseline cardiovascular data from the early versus late intervention trial with estradiol testing the menopausal hormone timing hypothesis. Menopause 22 (2015), 391–401.
7. 7 Manson, J.E., The ‘timing hypothesis’ for estrogen therapy in menopausal symptom management. Womens Health 11 (2015), 437–440.
8. 8 Chakrabarti, S., Morton, J.S., Davidge, S.T., Mechanisms of estrogen effects on the endothelium: an overview. Can J Cardiol 30 (2014), 705–712.
9. 9 Gilligan, D.M., Quyyumi, A.A., Cannon, R.O. 3rd, Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 89 (1994), 2545–2551.
10. 10 Stocco, C., Tissue physiology and pathology of aromatase. Steroids 77 (2012), 27–35.
11. 11 Weniger, J.P., Zeis, A., Aromatization of testosterone by the rat embryo testis. [in French] C R Seances Acad Sci III 296 (1983), 293–296.
12. 12 Tsugaya, M., Harada, N., Tozawa, K., et al. Aromatase mRNA levels in benign prostatic hyperplasia and prostate cancer. Int J Urol 3 (1996), 292–296.
13. 13 Trotter, A., Maier, L., Grill, H.J., Wudy, S.A., Pohlandt, F., 17beta-estradiol and progesterone supplementation in extremely low-birth-weight infants. Pediatr Res 45 (1999), 489–493.
14. 14 Ling, S., Komesaroff, P., Sudhir, K., Cellular mechanisms underlying the cardiovascular actions of oestrogens. Clin Sci 111 (2006), 107–118.
15. 15 Hong, Y., Li, H., Yuan, Y.C., Chen, S., Molecular characterization of aromatase. Ann N Y Acad Sci 1155 (2009), 112–120.
16. 16 Harada, N., Utsumi, T., Takagi, Y., Tissue-specific expression of the human aromatase cytochrome p-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis. Proc Natl Acad Sci U S A 90 (1993), 11312–11316.
17. 17 Bell, J.R., Mellor, K.M., Wollermann, A.C., et al. Aromatase deficiency confers paradoxical postischemic cardioprotection. Endocrinology 152 (2011), 4937–4947.
18. 18 Grohe, C., Kahlert, S., Lobbert, K., Vetter, H., Expression of oestrogen receptor alpha and beta in rat heart: role of local oestrogen synthesis. J Endocrinol 156 (1998), R1–R7.
19. 19 Jazbutyte, V., Stumpner, J., Redel, A., et al. Aromatase inhibition attenuates desflurane-induced preconditioning against acute myocardial infarction in male mouse heart in vivo. PLoS One, 7, 2012, e42032.
20. 20 Balthazart, J., Charlier, T.D., Cornil, C.A., et al. Sex differences in brain aromatase activity: genomic and non-genomic controls. Front Endocrinol, 2, 2011, 34.
21. 21 Kumar, P., Kamat, A., Mendelson, C.R., Estrogen receptor alpha (ERalpha) mediates stimulatory effects of estrogen on aromatase (CYP19) gene expression in human placenta. Mol Endocrinol 23 (2009), 784–793.
22. 22 Beitelshees, A.L., Johnson, J.A., Hames, M.L., et al. Aromatase gene polymorphisms are associated with survival among patients with cardiovascular disease in a sex-specific manner. PLoS One, 5, 2010, e15180.
23. 23 Grohe, C., Kahlert, S., Lobbert, K., et al. Cardiac myocytes and fibroblasts contain functional estrogen receptors. FEBS Lett 416 (1997), 107–112.
24. 24 Mahmoodzadeh, S., Eder, S., Nordmeyer, J., et al. Estrogen receptor alpha up-regulation and redistribution in human heart failure. FASEB J 20 (2006), 926–934.
25. 25 Taylor, A.H., Al-Azzawi, F., Immunolocalisation of oestrogen receptor beta in human tissues. J Mol Endocrinol 24 (2000), 145–155.
26. 26 Lizotte, E., Grandy, S.A., Tremblay, A., Allen, B.G., Fiset, C., Expression, distribution and regulation of sex steroid hormone receptors in mouse heart. Cell Physiol Biochem 23 (2009), 75–86.
27. 27 Knowlton, A.A., Lee, A.R., Estrogen and the cardiovascular system. Pharmacol Ther 135 (2012), 54–70.
28. 28 Bowling, M.R., Xing, D., Kapadia, A., et al. Estrogen effects on vascular inflammation are age dependent: role of estrogen receptors. Arterioscler Thromb Vasc Biol 34 (2014), 1477–1485.
29. 29 Holm, A., Nilsson, B.O., Identification and characterization of new mechanisms in vascular oestrogen signalling. Basic Clin Pharmacol Toxicol 113 (2013), 287–293.
30. 30 Barnabas, O., Wang, H., Gao, X.M., Role of estrogen in angiogenesis in cardiovascular diseases. J Geriatr Cardiol 10 (2013), 377–382.
31. 31 Jazbutyte, V., Kehl, F., Neyses, L., Pelzer, T., Estrogen receptor alpha interacts with 17beta-hydroxysteroid dehydrogenase type 10 in mitochondria. Biochem Biophys Res Commun 384 (2009), 450–454.
32. 32 Yang, S.H., Liu, R., Perez, E.J., et al. Mitochondrial localization of estrogen receptor beta. Proc Natl Acad Sci U S A 101 (2004), 4130–4135.
33. 33 Meyer, M.R., Haas, E., Prossnitz, E.R., Barton, M., Non-genomic regulation of vascular cell function and growth by estrogen. Mol Cell Endocrinol 308 (2009), 9–16.
34. 34 Deschamps, A.M., Murphy, E., Activation of a novel estrogen receptor, GPER, is cardioprotective in male and female rats. Am J Physiol Heart Circ Physiol 297 (2009), H1806–H1813.
35. 35 Jessup, J.A., Lindsey, S.H., Wang, H., Chappell, M.C., Groban, L., Attenuation of salt-induced cardiac remodeling and diastolic dysfunction by the gper agonist g-1 in female mren2.Lewis rats. PLoS One, 5, 2010, e15433.
36. 36 Leibowitz, D., Dresner-Pollak, R., Dvir, S., et al. Association of an estrogen receptor-alpha gene polymorphism with left ventricular mass. Blood Press 15 (2006), 45–50.
37. 37 Peter, I., Shearman, A.M., Vasan, R.S., et al. Association of estrogen receptor beta gene polymorphisms with left ventricular mass and wall thickness in women. Am J Hypertens 18 (2005), 1388–1395.
38. 38 Barone, I., Brusco, L., Fuqua, S.A., Estrogen receptor mutations and changes in downstream gene expression and signaling. Clin Cancer Res 16 (2010), 2702–2708.
39. 39 Kunnas, T., Silander, K., Karvanen, J., et al. Esr1 genetic variants, haplotypes and the risk of coronary heart disease and ischemic stroke in the Finnish population: a prospective follow-up study. Atherosclerosis 211 (2010), 200–202.
40. 40 Schuit, S.C., Oei, H.H., Witteman, J.C., et al. Estrogen receptor alpha gene polymorphisms and risk of myocardial infarction. JAMA 291 (2004), 2969–2977.
41. 41 Domingues-Montanari, S., Subirana, I., Tomas, M., Marrugat, J., Senti, M., Association between esr2 genetic variants and risk of myocardial infarction. Clin Chem 54 (2008), 1183–1189.
42. 42 Rexrode, K.M., Ridker, P.M., Hegener, H.H., et al. Polymorphisms and haplotypes of the estrogen receptor-beta gene (ESR2) and cardiovascular disease in men and women. Clin Chem 53 (2007), 1749–1756.
43. 43 Giess, M., Lattrich, C., Springwald, A., et al. GPR30 gene polymorphisms are associated with progesterone receptor status and histopathological characteristics of breast cancer patients. J Steriod Biochem Mol Biol 118 (2010), 7–12.
44. 44 Mauvais-Jarvis, F., Clegg, D.J., Hevener, A.L., The role of estrogens in control of energy balance and glucose homeostasis. Endocr Rev 34 (2013), 309–338.
45. 45 Gupte, A.A., Pownall, H.J., Hamilton, D.J., Estrogen: an emerging regulator of insulin action and mitochondrial function. J Diabetes Res, 2015, 2015, 916585.
46. 46 Carr, M.C., The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 88 (2003), 2404–2411.
47. 47 Wallen, W.J., Belanger, M.P., Wittnich, C., Sex hormones and the selective estrogen receptor modulator tamoxifen modulate weekly body weights and food intakes in adolescent and adult rats. J Nutr 131 (2001), 2351–2357.
48. 48 Heine, P.A., Taylor, J.A., Iwamoto, G.A., Lubahn, D.B., Cooke, P.S., Increased adipose tissue in male and female estrogen receptor-alpha knockout mice. Proc Natl Acad Sci U S A 97 (2000), 12729–12734.
49. 49 Ribas, V., Nguyen, M.T., Henstridge, D.C., et al. Impaired oxidative metabolism and inflammation are associated with insulin resistance in ERalpha-deficient mice. Am J Physiol Endocrinol Metab 298 (2010), E304–E319.
50. 50 Chen, Y., Zhang, Z., Hu, F., et al. 17beta-estradiol prevents cardiac diastolic dysfunction by stimulating mitochondrial function: a preclinical study in a mouse model of a human hypertrophic cardiomyopathy mutation. J Steroid Biochem Mol Biol 147 (2015), 92–102.
51. 51 Arias-Loza, P.A., Kreissl, M.C., Kneitz, S., et al. The estrogen receptor-alpha is required and sufficient to maintain physiological glucose uptake in the mouse heart. Hypertension 60 (2012), 1070–1077.
52. 52 Devanathan, S., Whitehead, T., Schweitzer, G.G., et al. An animal model with a cardiomyocyte-specific deletion of estrogen receptor alpha: functional, metabolic, and differential network analysis. PLoS One, 9, 2014, e101900.
53. 53 Barros, R.P., Machado, U.F., Warner, M., Gustafsson, J.A., Muscle glut4 regulation by estrogen receptors ERbeta and ERalpha. Proc Natl Acad Sci U S A 103 (2006), 1605–1608.
54. 54 Ramjiawan, A., Bagchi, R.A., Albak, L., Czubryt, M.P., Mechanism of cardiomyocyte PGC-1alpha gene regulation by ERRalpha. Biochem Cell Biol 91 (2013), 148–154.
55. 55 Stein, R.A., McDonnell, D.P., Estrogen-related receptor alpha as a therapeutic target in cancer. Endocr Relat Cancer 13:suppl 1 (2006), S25–S32.
56. 56 Ohlsson, C., Hellberg, N., Parini, P., et al. Obesity and disturbed lipoprotein profile in estrogen receptor-alpha-deficient male mice. Biochem Biophys Res Commun 278 (2000), 640–645.
57. 57 Roesch, D.M., Effects of selective estrogen receptor agonists on food intake and body weight gain in rats. Physiol Behav 87 (2006), 39–44.
58. 58 Yepuru, M., Eswaraka, J., Kearbey, J.D., et al. Estrogen receptor-{beta}-selective ligands alleviate high-fat diet- and ovariectomy-induced obesity in mice. J Biol Chem 285 (2010), 31292–31303.
59. 59 Simpkins, J.W., Yang, S.H., Sarkar, S.N., Pearce, V., Estrogen actions on mitochondria–physiological and pathological implications. Mol Cell Endocrinol 290 (2008), 51–59.
60. 60 Gabel, S.A., Walker, V.R., London, R.E., et al. Estrogen receptor beta mediates gender differences in ischemia/reperfusion injury. J Mol Cell Cardiol 38 (2005), 289–297.
61. 61 Hsieh, Y.C., Yu, H.P., Suzuki, T., et al. Upregulation of mitochondrial respiratory complex IV by estrogen receptor-beta is critical for inhibiting mitochondrial apoptotic signaling and restoring cardiac functions following trauma-hemorrhage. J Mol Cell Cardiol 41 (2006), 511–521.
62. 62 Hsieh, Y.C., Choudhry, M.A., Yu, H.P., et al. Inhibition of cardiac PGC-1alpha expression abolishes ERbeta agonist-mediated cardioprotection following trauma-hemorrhage. FASEB J 20 (2006), 1109–1117.
63. 63 Pelzer, T., Schumann, M., Neumann, M., et al. 17beta-estradiol prevents programmed cell death in cardiac myocytes. Biochem Biophys Res Commun 268 (2000), 192–200.
64. 64 Pelzer, T., Neumann, M., de Jager, T., Jazbutyte, V., Neyses, L., Estrogen effects in the myocardium: inhibition of NF-kappab DNA binding by estrogen receptor-alpha and -beta. Biochem Biophys Res Commun 286 (2001), 1153–1157.
65. 65 Patten, R.D., Pourati, I., Aronovitz, M.J., et al. 17beta-estradiol reduces cardiomyocyte apoptosis in vivo and in vitro via activation of phospho-inositide-3 kinase/Akt signaling. Circ Res 95 (2004), 692–699.
66. 66 Satoh, M., Matter, C.M., Ogita, H., et al. Inhibition of apoptosis-regulated signaling kinase-1 and prevention of congestive heart failure by estrogen. Circulation 115 (2007), 3197–3204.
67. 67 Cong, B., Zhu, X., Cao, B., et al. Estrogens protect myocardium against ischemia/reperfusion insult by up-regulation of CRH receptor type 2 in female rats. Int J Cardiol 168 (2013), 4755–4760.
68. 68 Liu, H., Yanamandala, M., Lee, T.C., Kim, J.K., Mitochondrial p38beta and manganese superoxide dismutase interaction mediated by estrogen in cardiomyocytes. PLoS One, 9, 2014, e85272.
69. 69 Liu, H., Pedram, A., Kim, J.K., Oestrogen prevents cardiomyocyte apoptosis by suppressing p38alpha-mediated activation of p53 and by down-regulating p53 inhibition on p38beta. Cardiovasc Res 89 (2011), 119–128.
70. 70 Kim, J.K., Pedram, A., Razandi, M., Levin, E.R., Estrogen prevents cardiomyocyte apoptosis through inhibition of reactive oxygen species and differential regulation of p38 kinase isoforms. J Biol Chem 281 (2006), 6760–6767.
71. 71 Liou, C.M., Yang, A.L., Kuo, C.H., et al. Effects of 17beta-estradiol on cardiac apoptosis in ovariectomized rats. Cell Biochem Funct 28 (2010), 521–528.
72. 72 Wang, M., Crisostomo, P., Wairiuko, G.M., Meldrum, D.R., Estrogen receptor-alpha mediates acute myocardial protection in females. Am J Physiol Heart Circ Physiol 290 (2006), H2204–H2209.
73. 73 Wang, M., Crisostomo, P.R., Markel, T., et al. Estrogen receptor beta mediates acute myocardial protection following ischemia. Surgery 144 (2008), 233–238.
74. 74 Liu, C.J., Lo, J.F., Kuo, C.H., et al. Akt mediates 17beta-estradiol and/or estrogen receptor-alpha inhibition of LPS-induced tumor necresis factor-alpha expression and myocardial cell apoptosis by suppressing the JNK1/2-NFkappaB pathway. J Cell Mol Med 13 (2009), 3655–3667.
75. 75 Cao, J., Zhu, T., Lu, L., et al. Estrogen induces cardioprotection in male C57BL/6J mice after acute myocardial infarction via decreased activity of matrix metalloproteinase-9 and increased Akt-Bcl-2 anti-apoptotic signaling. Int J Mol Med 28 (2011), 231–237.
76. 76 Li, X., Huang, J., Yi, P., et al. Single-chain estrogen receptors (ERs) reveal that the ERalpha/beta heterodimer emulates functions of the ERalpha dimer in genomic estrogen signaling pathways. Mol Cell Biol 24 (2004), 7681–7694.
77. 77 Cowley, S.M., Hoare, S., Mosselman, S., Parker, M.G., Estrogen receptors alpha and beta form heterodimers on DNA. J Biol Chem 272 (1997), 19858–19862.
78. 78 Wang, L., Gu, H., Turrentine, M., Wang, M., Estradiol treatment promotes cardiac stem cell (CSC)-derived growth factors, thus improving CSC-mediated cardioprotection after acute ischemia/reperfusion. Surgery 156 (2014), 243–252.
79. 79 Han, H.J., Heo, J.S., Lee, Y.J., Estradiol-17beta stimulates proliferation of mouse embryonic stem cells: involvement of MAPKs and CDKs as well as protooncogenes. Am J Physiol Cell Physiol 290 (2006), C1067–C1075.
80. 80 Hamada, H., Kim, M.K., Iwakura, A., et al. Estrogen receptors alpha and beta mediate contribution of bone marrow-derived endothelial progenitor cells to functional recovery after myocardial infarction. Circulation 114 (2006), 2261–2270.
81. 81 Brinckmann, M., Kaschina, E., Altarche-Xifro, W., et al. Estrogen receptor alpha supports cardiomyocytes indirectly through post-infarct cardiac c-kit+ cells. J Mol Cell Cardiol 47 (2009), 66–75.
82. 82 Pelzer, T., Jazbutyte, V., Hu, K., et al. The estrogen receptor-alpha agonist 16alpha-LE2 inhibits cardiac hypertrophy and improves hemodynamic function in estrogen-deficient spontaneously hypertensive rats. Cardiovasc Res 67 (2005), 604–612.
83. 83 Jazbutyte, V., Arias-Loza, P.A., Hu, K., et al. Ligand-dependent activation of ER{beta} lowers blood pressure and attenuates cardiac hypertrophy in ovariectomized spontaneously hypertensive rats. Cardiovasc Res 77 (2008), 774–781.
84. 84 Donaldson, C., Eder, S., Baker, C., et al. Estrogen attenuates left ventricular and cardiomyocyte hypertrophy by an estrogen receptor-dependent pathway that increases calcineurin degradation. Circ Res 104 (2009), 265–275 11p following 275.
85. 85 Gurgen, D., Kusch, A., Klewitz, R., et al. Sex-specific mTOR signaling determines sexual dimorphism in myocardial adaptation in normotensive DOCA-salt model. Hypertension 61 (2013), 730–736.
86. 86 van Eickels, M., Grohe, C., Cleutjens, J.P., et al. 17beta-estradiol attenuates the development of pressure-overload hypertrophy. Circulation 104 (2001), 1419–1423.
87. 87 Pedram, A., Razandi, M., Narayanan, R., et al. Estrogen regulates histone deacetylases to prevent cardiac hypertrophy. Mol Biol Cell 24 (2013), 3805–3818.
88. 88 Dworatzek, E., Mahmoodzadeh, S., Schubert, C., et al. Sex differences in exercise-induced physiological myocardial hypertrophy are modulated by oestrogen receptor beta. Cardiovasc Res 102 (2014), 418–428.
89. 89 Kararigas, G., Nguyen, B.T., Jarry, H., Estrogen modulates cardiac growth through an estrogen receptor alpha-dependent mechanism in healthy ovariectomized mice. Mol Cell Endocrinol 382 (2014), 909–914.
90. 90 McDermott-Roe, C., Ye, J., Ahmed, R., et al. Endonuclease G is a novel determinant of cardiac hypertrophy and mitochondrial function. Nature 478 (2011), 114–118.
91. 91 Pereira, R.T., Porto, C.S., Abdalla, F.M., Ovariectomy and 17beta-estradiol replacement play a role on the expression of endonuclease-G and phosphorylated cyclic AMP response element-binding (CREB) protein in hippocampus. Mol Cell Endocrinol 382 (2014), 227–233.
92. 92 Nakagawa, M., Ooie, T., Ou, B., et al. Gender differences in autonomic modulation of ventricular repolarization in humans. J Cardiovasc Electrophysiol 16 (2005), 278–284.
93. 93 Bernal, O., Moro, C., Cardiac arrhythmias in women. [in Spanish] Rev Esp Cardiol 59 (2006), 609–618.
94. 94 McHugh, N.A., Cook, S.M., Schairer, J.L., Bidgoli, M.M., Merrill, G.F., Ischemia- and reperfusion-induced ventricular arrhythmias in dogs: effects of estrogen. Am J Physiol 268 (1995), H2569–H2573.
95. 95 Anderson, S.E., Kirkland, D.M., Beyschau, A., Cala, P.M., Acute effects of 17beta-estradiol on myocardial pH, Na+, and Ca2+ and ischemia-reperfusion injury. Am J Physiol Cell Physiol 288 (2005), C57–C64.
96. 96 Node, K., Kitakaze, M., Kosaka, H., et al. Amelioration of ischemia- and reperfusion-induced myocardial injury by 17beta-estradiol: role of nitric oxide and calcium-activated potassium channels. Circulation 96 (1997), 1953–1963.
97. 97 Ribeiro, R.F. Jr., Pavan, B.M., Potratz, F.F., et al. Myocardial contractile dysfunction induced by ovariectomy requires at1 receptor activation in female rats. Cell Physiol Biochem 30 (2012), 1–12.
98. 98 Parks, R.J., Howlett, S.E., Sex differences in mechanisms of cardiac excitation-contraction coupling. Pflugers Arch 465 (2013), 747–763.
99. 99 Johnson, B.D., Zheng, W., Korach, K.S., et al. Increased expression of the cardiac L-type calcium channel in estrogen receptor-deficient mice. J Gen Physiol 110 (1997), 135–140.
100. 100 Marni, F., Wang, Y., Morishima, M., et al. 17 beta-estradiol modulates expression of low-voltage-activated Ca(v)3.2 T-type calcium channel via extracellularly regulated kinase pathway in cardiomyocytes. Endocrinology 150 (2009), 879–888.
101. 101 Nakajima, T., Iwasawa, K., Oonuma, H., et al. Antiarrhythmic effect and its underlying ionic mechanism of 17beta-estradiol in cardiac myocytes. Br J Pharmacol 127 (1999), 429–440.
102. 102 El Gebeily, G., El Khoury, N., Mathieu, S., Brouillette, J., Fiset, C., Estrogen regulation of the transient outward k(+) current involves estrogen receptor alpha in mouse heart. J Mol Cell Cardiol 86 (2015), 85–94.
103. 103 Kulpa, J., Chinnappareddy, N., Pyle, W.G., Rapid changes in cardiac myofilament function following the acute activation of estrogen receptor-alpha. PLoS One, 7, 2012, e41076.
104. 104 Ullrich, N.D., Krust, A., Collins, P., MacLeod, K.T., Genomic deletion of estrogen receptors ERalpha and ERbeta does not alter estrogen-mediated inhibition of Ca2+ influx and contraction in murine cardiomyocytes. Am J Physiol Heart Circ Physiol 294 (2008), H2421–H2427.
105. 105 Gao, Q., Liu, S., Guo, F., et al. Nonylphenol affects myocardial contractility and L-type Ca(2+) channel currents in a non-monotonic manner via G protein-coupled receptor 30. Toxicology 334 (2015), 122–129.